|
1
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Onyoh EF, Hsu WF, Chang LC, Lee YC, Wu MS
and Chiu HM: The rise of colorectal cancer in asia: Epidemiology,
screening, and management. Curr Gastroenterol Rep. 21:362019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rahman R, Asombang AW and Ibdah JA:
Characteristics of gastric cancer in Asia. World J Gastroenterol.
20:4483–4490. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wick JY: Aspirin: A history, A love story.
Consult Pharm. 27:322–329. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Amsterdam EA, Wenger NK, Brindis RG, Casey
DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC,
et al: 2014 AHA/ACC Guideline for the management of patients with
Non-ST-Elevation acute coronary syndromes: Executive summary: A
Report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines. J Am Colle Cardiol.
64:2645–2687. 2014. View Article : Google Scholar
|
|
7
|
Antithrombotic Trialists' (ATT)
Collaboration, . Baigent C, Blackwell L, Collins R, Emberson J,
Godwin J, Peto R, Buring J, Hennekens C, Kearney P, et al: Aspirin
in the primary and secondary prevention of vascular disease:
Collaborative meta-analysis of individual participant data from
randomised trials. Lancet. 373:1849–1860. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roffi M, Patrono C, Collet J, Mueller C,
Valgimigli M, Andreotti F, Bax J, Borger M, Brotons C, Chew DP, et
al: 2015 ESC Guidelines for the management of acute coronary
syndromes in patients presenting without persistent ST-segment
elevation. Task Force for the management of acute coronary
syndromes in patients presenting without persistent ST-Segment
Elevation of the European Society of Cardiology (ESC). G Ital
Cardiol (Rome). 17:831–872. 2016.(In Italian). PubMed/NCBI
|
|
9
|
Smith DK, Demetriou T and Weber C: Aspirin
for primary prevention: USPSTF recommendations for CVD and
colorectal cancer. J Fam Pract. 68:146–151. 2019.PubMed/NCBI
|
|
10
|
Ventura L, Miccinesi G, Barchielli A,
Manneschi G, Puliti D, Mantellini P, Orso F and Zappa M: Does
low-dose aspirin use for cardiovascular disease prevention reduce
colorectal cancer deaths? A comparison of two cohorts in the
Florence district, Italy. Eur J Cancer Prev. 27:134–139. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bibbins-Domingo K; U.S. Preventive
Services Task Force, : Aspirin use for the primary prevention of
cardiovascular disease and colorectal cancer: U.S. Preventive
Services Task Force recommendation statement. Ann Intern Med.
164:836–845. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cea Soriano L, Soriano-Gabarró M and
García Rodríguez LA: Incidence of colorectal cancer in new users
and non-users of low-dose aspirin without existing cardiovascular
disease: A cohort study using The Health Improvement Network. Int J
Cardiol. 248:376–381. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Soon S, Chia WJ, Redekop K and Wee HL: A
Cost-effectiveness analysis of aspirin in the primary prevention of
cardiovascular diseases and colorectal cancer. Value Health.
18:A4622015. View Article : Google Scholar
|
|
14
|
Lanas A and Gargallo CJ: Management of
low-dose aspirin and clopidogrel in clinical practice: A
gastrointestinal perspective. J Gastroenterol. 50:626–637. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lanas A and Scheiman J: Low-dose aspirin
and upper gastrointestinal damage: Epidemiology, prevention and
treatment. Curr Med Res Opin. 23:163–173. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yuhara H, Corley DA, Nakahara F, Nakajima
T, Koike J, Igarashi M, Suauki T and Mine T: Aspirin and
non-aspirin NSAIDs increase risk of colonic diverticular bleeding:
A systematic review and meta-analysis. J Gastroenterol.
49:992–1000. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Strum WB: Colorectal adenomas. N Engl J
Med. 374:1065–1075. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Giovannucci E, Rimm E, Stampfer M, Colditz
G, Ascherio A and Willett WC: Aspirin use and the risk for
colorectal cancer and adenoma in male health professionals. Ann
Intern Med. 121:241–246. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thun MJ, Namboodiri MM and Heath C Jr:
Aspirin use and reduced risk of fatal colon cancer. N Engl J Med.
325:1593–1596. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sandler R, Halabi S, Baron J, Budinger S,
Paskett E, Keresztes R, Petrelli N, Pipas J, Karp D, Loprinzi CL,
et al: A randomized trial of aspirin to prevent colorectal adenomas
in patients with previous colorectal cancer. N Engl J Med.
348:883–890. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baron JA, Cole BF, Sandler RS, Haile RW,
Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R,
Burke CA, et al: A randomized trial of aspirin to prevent
colorectal adenomas. N Engl J Med. 348:891–899. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Half E, Bercovich D and Rozen P: Familial
adenomatous polyposis. Orphanet J Rare Dis. 4:222009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aihara H, Kumar N and Thompson CC:
Diagnosis, surveillance, and treatment strategies for familial
adenomatous polyposis: Rationale and update. Eur J Gastroenterol
Hepatol. 26:255–262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Iwama T, Tamura K, Morita T, Hirai T,
Hasegawa H, Koizumi K, Shirouzu K, Sugihara K, Yamamura T, Muto T,
et al: A clinical overview of familial adenomatous polyposis
derived from the database of the polyposis registry of Japan. Int J
Clin Oncol. 9:308–316. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jasperson K and Burt RW: The genetics of
colorectal cancer. Surg Oncol Clin N Am. 24:683–703. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ishikawa H: Chemoprevention of
carcinogenesis in familial tumors. Int J Clin Oncol. 9:299–303.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ishikawa H, Wakabayashi K, Suzuki S, Mutoh
M, Hirata K, Nakamura T, Takeyama I, Kawano A, Gondo N, Abe T, et
al: Preventive effects of low-dose aspirin on colorectal adenoma
growth in patients with familial adenomatous polyposis:
Double-blind, randomized clinical trial. Cancer Med. 2:50–56. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Burn J, Bishop DT, Chapman PD, Elliott F,
Bertario L, Dunlop MG, Eccles D, Ellis A, Evans DG, Fodde R, et al:
A randomized placebo-controlled prevention trial of aspirin and/or
resistant starch in young people with familial adenomatous
polyposis. Cancer Prev Res (Phila). 4:655–665. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cea Soriano L, Soriano-Gabarró M and
Garcia Rodríiguez LA: Incidence of colorectal cancer in new users
and non-users of low-dose aspirin without existing cardiovascular
disease: A cohort study using The Health Improvement Network. Int J
Cardiol. 248:376–381. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cao Y, Nishihara R, Wu K, Wang M, Ogino S,
Willett WC, Spiegelman D, Fuchs CS, Giovannucci EL and Chan AT:
Population-wide impact of long-term use of aspirin and the risk for
cancer. JAMA Oncol. 2:762–769. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thun MJ, Henley SJ and Patrono C:
Nonsteroidal Anti-inflammatory drugs as anticancer agents:
Mechanistic, pharmacologic, and clinical issues. J Nat Cancer Inst.
94:252–266. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rothwell PM, Price JF, Fowkes FG,
Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M,
Mehta Z and Meade TW: Short-term effects of daily aspirin on cancer
incidence, mortality, and non-vascular death: Analysis of the time
course of risks and benefits in 51 randomised controlled trials.
Lancet. 379:1602–1612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chubak J, Whitlock EP, Williams SB,
Kamineni A, Burda BU, Buist DS and Anderson ML: Aspirin for the
prevention of cancer incidence and mortality: Systematic evidence
reviews for the U.S. Preventive Services Task Force. Ann Intern
Med. 164:814–825. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Flossmann E and Rothwell PM; British
Doctors Aspirin Trial and the UK-TIA Aspirin Trial, : Effect of
aspirin on long-term risk of colorectal cancer: Consistent evidence
from randomised and observational studies. Lancet. 369:1603–1613.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rothwell PM, Wilson M, Elwin CE, Norrving
B, Algra A, Warlow CP and Meade TW: Long-term effect of aspirin on
colorectal cancer incidence and mortality: 20-year follow-up of
five randomised trials. Lancet. 376:1741–1750. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li XF, Xu BZ and Wang SZ: Aspirin inhibits
the proliferation and migration of gastric cancer cells in
p53-knockout mice. Oncol Lett. 12:3183–3186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ratnasinghe LD, Graubard BI, Kahle L,
Tangrea JA, Taylor PR and Hawk E: Aspirin use and mortality from
cancer in a prospective cohort study. Anticancer Res. 24:3177–3184.
2004.PubMed/NCBI
|
|
38
|
Thun MJ, Namboodiri MM, Calle EE, Flanders
WD and Heath CW Jr: Aspirin use and risk of fatal cancer. Cancer
Res. 53:1322–1327. 1993.PubMed/NCBI
|
|
39
|
Rothwell PM, Fowkes FGR, Belch JFF, Ogawa
H, Warlow CP and Meade TW: Effect of daily aspirin on long-term
risk of death due to cancer: Analysis of individual patient data
from randomised trials. Lancet. 377:31–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Farrow DC, Vaughan TL, Hansten PD,
Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne
ST, et al: Use of aspirin and other nonsteroidal anti-inflammatory
drugs and risk of esophageal and gastric cancer. Cancer Epidemiol
Biomarkers Prev. 7:97–102. 1998.PubMed/NCBI
|
|
41
|
Vaughan TL, Dong LM, Blount PL, Ayub K,
Odze RD, Sanchez CA, Rabinovitch PS and Reid BJ: Non-steroidal
anti-inflammatory drugs and risk of neoplastic progression in
Barrett's oesophagus: A prospective study. Lancet Oncol. 6:945–952.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
González-Pérez A, Rodríguez LAG and
LópezRidaura R: Effects of non-steroidal anti-inflammatory drugs on
cancer sites other than the colon and rectum: A meta-analysis. BMC
Cancer. 3:282003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu JF, Jamieson GG, Wu TC, Zhu GJ and
Drew PA: A preliminary study on the postoperative survival of
patients given aspirin after resection for squamous cell carcinoma
of the esophagus or adenocarcinoma of the cardia. Ann Surg Oncol.
16:1397–1402. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Frouws MA, Bastiaannet E, Langley RE, Chia
WK, van Herk-Sukel MP, Lemmens VE, Putter H, Hartgrink HH, Bonsing
BA, Van de Velde CJ, et al: Effect of low-dose aspirin use on
survival of patients with gastrointestinal malignancies; an
observational study. Br J Cancer. 116:405–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Macfarlane TV, Murchie P and Watson MC:
Aspirin and other non-steroidal anti-inflammatory drug
prescriptions and survival after the diagnosis of head and neck and
oesophageal cancer. Cancer Epidemiol. 39:1015–1022. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bosetti C, Rosato V, Gallus S, Cuzick J
and La Vecchia C: Aspirin and cancer risk: A quantitative review to
2011. Ann Oncol. 23:1403–1415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jankowski JAZ, de Caestecker J, Love SB,
Reilly G, Watson P, Sanders S, Ang Y, Morris D, Bhandari P, Brooks
C, et al: Esomeprazole and aspirin in Barrett's oesophagus
(AspECT): A randomised factorial trial. Lancet. 392:400–408. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Spence AD, Busby J, Johnston BT, Baron JA,
Hughes CM, Coleman HG and Cardwell CR: Low-Dose aspirin use does
not increase survival in 2 independent population-based cohorts of
patients with esophageal or gastric cancer. Gastroenterology.
154:849–860.e1. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Choi JH, Lee SH, Huh G, Chun JW, You MS,
Paik WH, Ryu JK and Kim YT: The association between use of statin
or aspirin and pancreatic ductal adenocarcinoma: A nested
case-control study in a Korean nationwide cohort. Cancer Med.
8:7419–7430. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sahasrabuddhe VV, Gunja MZ, Graubard BI,
Trabert B, Schwartz LM, Park Y, Hollenbeck AR, Freedman ND and
McGlynn KA: Nonsteroidal Anti-inflammatory drug use, chronic liver
disease, and hepatocellular carcinoma. J Natl Cancer Inst.
104:1808–1814. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Coogan PF, Rosenberg L, Palmer JR, Strom
BL, Zauber AG, Stolley PD and Shapiro S: Nonsteroidal
anti-inflammatory drugs and risk of digestive cancers at sites
other than the large bowel. Cancer Epidemiol Biomarkers Prev.
9:119–123. 2000.PubMed/NCBI
|
|
52
|
Petrick JL, Sahasrabuddhe VV, Chan AT,
Alavanja MC, Beane-Freeman LE, Buring JE, Chen J, Chong DQ,
Freedman ND, Fuchs CS, et al: NSAID use and risk of hepatocellular
carcinoma and intrahepatic cholangiocarcinoma: The liver cancer
pooling project. Cancer Prev Res. 8:1156–1162. 2015. View Article : Google Scholar
|
|
53
|
Singh S, Singh PP, Roberts LR and Sanchez
W: Chemopreventive strategies in hepatocellular carcinoma. Nat Rev
Gastroenterol Hepatol. 11:45–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hawk ET, Umar A and Viner JL: Colorectal
cancer chemoprevention-an overview of the science 1 1 This article
was prepared in our capacity as employees of the U.S. Federal
Government. Gastroenterology. 126:1423–1447. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Elwood PC, Gallagher AM, Duthie GG, Mur LA
and Morgan G: Aspirin, salicylates, and cancer. Lancet.
373:1301–1309. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pasche B, Wang M, Pennison M and Jimenez
H: Prevention and treatment of cancer with aspirin: Where do we
stand? Semin Oncol. 41:397–401. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mahboubi Rabbani SMI and Zarghi A:
Selective COX-2 inhibitors as anticancer agents: A patent review
(2014–2018). Expert Opin Ther Pat. 29:407–427. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Poorani R, Bhatt AN, Dwarakanath BS and
Das UN: COX-2, aspirin and metabolism of arachidonic,
eicosapentaenoic and docosahexaenoic acids and their physiological
and clinical significance. Eur J Pharmacol. 785:116–132. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang D and Dubois RN: Prostaglandins and
cancer. Gut. 55:115–122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chell S, Kaidi A, Williams AC and
Paraskeva C: Mediators of PGE2 synthesis and signalling downstream
of COX-2 represent potential targets for the prevention/treatment
of colorectal cancer. Biochim Biophys Acta. 1766:104–119.
2006.PubMed/NCBI
|
|
61
|
Chan AT, Ogino S and Fuchs CS: Aspirin and
the risk of colorectal cancer in relation to the expression of
COX-2. N Engl J Med. 356:2131–2142. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhang L, Yu J, Park BH, Kinzler KW and
Vogelstein B: Role of BAX in the apoptotic response to anticancer
agents. Science. 290:989–992. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhang Z and Dubois RN: Par-4, a
proapoptotic gene, is regulated by NSAIDs in human colon carcinoma
cells. Gastroenterol. 118:1012–1017. 2000. View Article : Google Scholar
|
|
64
|
Kashfi K and Rigas B: Non-COX-2 targets
and cancer: Expanding the molecular target repertoire of
chemoprevention. Biochem Pharmacol. 70:969–986. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Shureiqi I, Xu X, Chen D, Lotan R, Morris
JS, Fischer SM and Lippman SM: Nonsteroidal anti-inflammatory drugs
induce apoptosis in esophageal cancer cells by restoring
15-lipoxygenase-1 expression. Cancer Res. 61:4879–4884.
2001.PubMed/NCBI
|
|
66
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
McIlhatton MA, Tyler J, Burkholder S,
Ruschoff J, Rigas B, Kopelovich L and Fishel R: Nitric
Oxide-donating aspirin derivatives suppress microsatellite
instability in mismatch repair-deficient and hereditary
nonpolyposis colorectal cancer cells. Cancer Res. 67:10966–10975.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Rüschoff J, Wallinger S, Dietmaier W,
Bocker T, Brockhoff G, Hofstädter F and Fishel R: Aspirin
suppresses the mutator phenotype associated with hereditary
nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad
Sci USA. 95:11301–11306. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Goel A, Chang DK, Ricciardiello L, Gasche
C and Boland CR: A novel mechanism for aspirin-mediated growth
inhibition of human colon cancer cells. Clin Cancer Res. 9:383–390.
2003.PubMed/NCBI
|
|
70
|
Huang Z, Fang W, Liu W, Wang L, Liu B and
Liu S and Liu S: Aspirin induces Beclin-1-dependent autophagy of
human hepatocellular carcinoma cell. Eur J Pharmacol. 823:58–64.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Bhattacharya A and Eissa NT: Autophagy and
autoimmunity crosstalks. Front Immunol. 4:882013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Henry WS, Laszewski T, Tsang T, Beca F,
Beck AH, McAllister SS and Toker A: Aspirin suppresses growth in
PI3K-mutant breast cancer by activating AMPK and inhibiting mTORC1
signaling. Cancer Res. 77:790–801. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Liu W, Jiang Y, Sun J, Geng S, Pan Z,
Prinz RA, Wang C, Sun J, Jiao X and Xu X: Activation of
TGF-β-activated kinase 1 (TAK1) restricts Salmonella Typhimurium
growth by inducing AMPK activation and autophagy. Cell Death Dis.
9:5702018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hardie DG, Ross FA and Hawley SA:
AMP-Activated protein kinase: A target for drugs both ancient and
modern. Chem Biol. 19:1222–1236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kostadinov RL, Kuhner MK, Li X, Sanchez
CA, Galipeau PC, Paulson TG, Sather CL, Srivastava A, Odze RD,
Blount PL, et al: NSAIDs modulate clonal evolution in Barrett's
esophagus. PLoS Genet. 9:e10035532013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Drew DA, Cao Y and Chan AT: Aspirin and
colorectal cancer: The promise of precision chemoprevention. Nat
Rev Cancer. 16:173–186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Gala MK and Chan AT: Molecular pathways:
Aspirin and Wnt signaling-a molecularly targeted approach to cancer
prevention and treatment. Clin Cancer Res. 21:1543–1548. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yeomans ND, Lanas AI, Talley NJ, Thomson
AB, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Långström G,
Naesdal J, Serrano P, et al: Prevalence and incidence of
gastroduodenal ulcers during treatment with vascular protective
doses of aspirin. Aliment Pharmacol Ther. 22:795–801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Cayla G, Collet JP, Silvain J, Thiefin G,
Woimant F and Montalescot G: Prevalence and clinical impact of
Upper Gastrointestinal Symptoms in subjects treated with low dose
aspirin: The UGLA survey. Int J Cardiol. 156:69–75. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Biondi-Zoccai GG, Lotrionte M, Agostoni P,
Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I and Sangiorgi G:
A systematic review and meta-analysis on the hazards of
discontinuing or not adhering to aspirin among 50,279 patients at
risk for coronary artery disease. Eur Heart J. 27:2667–2674. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Baron JA, Senn S, Voelker M, Lanas A,
Laurora I, Thielemann W, Bruckner A and McCarthy D:
Gastrointestinal adverse effects of short-term aspirin use: A
meta-analysis of published randomized controlled trials. Drugs R D.
13:9–16. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Cayla G, Collet JP, Silvain J, Thiefin G,
Woimant F and Montalescot G: Prevalence and clinical impact of
Upper Gastrointestinal Symptoms in subjects treated with low dose
aspirin: The UGLA survey. Int J Cardiol. 156:69–75. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yeomans ND and Naesdal J: Systematic
review: Ulcer definition in NSAID ulcer prevention trials. Aliment
Pharmacol Ther. 27:465–472. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Cryer B and Feldman M: Effects of very low
dose daily, long-term aspirin therapy on gastric, duodenal, and
rectal prostaglandin levels and on mucosal injury in healthy
humans. Gastroenterology. 117:17–25. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Papatheodoridis GV, Sougioultzis S and
Archimandritis AJ: Effects of Helicobacter pylori and
nonsteroidal anti-inflammatory drugs on peptic ulcer disease:
Systematic review. Clin Gastroenterol Hepatol. 4:130–142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Huang JQ, Sridhar S and Hunt RH: Role of
Helicobacter pylori infection and non-steroidal
anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis.
Lancet. 359:14–22. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Thorat MA and Cuzick J: Prophylactic use
of aspirin: Systematic review of harms and approaches to mitigation
in the general population. Eur J Epidemiol. 30:5–18. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Iwamoto J, Mizokami Y, Shimokobe K, Ito M,
Hirayama T, Saito Y, Ikegami T, Honda A and Matsuzaki Y: Clinical
features of gastroduodenal ulcer in Japanese patients taking
low-dose aspirin. Dig Dis Sci. 55:2270–2274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Garcia Rodriguez LA, Martin-Perez M,
Hennekens CH, Rothwell PM and Lanas A: Bleeding Risk with long-term
low-dose aspirin: A systematic review of observational studies.
PLoS One. 11:e01600462016. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
McNeil JJ, Wolfe R, Woods RL, Tonkin AM,
Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, et
al: Effect of aspirin on cardiovascular events and bleeding in the
healthy elderly. N Engl J Med. 379:1509–1518. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
de Abajo FJ and García Rodríguez LA: Risk
of upper gastrointestinal bleeding and perforation associated with
low-dose aspirin as plain and enteric-coated formulations. BMC Clin
Pharmacol. 1:12001. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Lanas A, Serrano P, Bajador E, Esteva F,
Benito R and Sáinz R: Evidence of aspirin use in both upper and
lower gastrointestinal perforation. Gastroenterology. 112:683–689.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Yamada A, Sugimoto T, Kondo S, Ohta M,
Watabe H, Maeda S, Togo G, Yamaji Y, Ogura K, Okamoto M, et al:
Assessment of the risk factors for colonic diverticular hemorrhage.
Dis Colon Rectum. 51:116–120. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Lanas Á, Carrera-Lasfuentes P, Arguedas Y,
García S, Bujanda L, Calvet X, Ponce J, Perez-Aísa Á, Castro M,
Muñoz M, et al: Risk of upper and lower gastrointestinal bleeding
in patients taking nonsteroidal anti-inflammatory drugs,
antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol.
13:906–912.e2. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Hirata Y, Kataoka H, Shimura T, Mizushima
T, Mizoshita T, Tanida S, Kamiya T and Joh T: Incidence of
gastrointestinal bleeding in patients with cardiovascular disease:
Buffered aspirin versus enteric-coated aspirin. Scand J
Gastroenterol. 46:803–809. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Nagata N, Niikura R, Aoki T, Shimbo T,
Kishida Y, Sekine K, Tanaka S, Watanabe K, Sakurai T, Yokoi C, et
al: Colonic diverticular hemorrhage associated with the use of
nonsteroidal anti-inflammatory drugs, low-dose aspirin,
antiplatelet drugs, and dual therapy. J Gastroenterol Hepatol.
29:1786–1793. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Reichert MC, Krawczyk M, Appenrodt B,
Casper M, Friesenhahn-Ochs B, Grünhage F, Jüngst C, Zimmer V,
Lammert F and Dauer M: Selective association of nonaspirin NSAIDs
with risk of diverticulitis. Int J Colorectal Dis. 33:423–430.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Strate LL, Liu YL, Huang ES, Giovannucci
EL and Chan AT: Use of aspirin or nonsteroidal anti-inflammatory
drugs increases risk for diverticulitis and diverticular bleeding.
Gastroenterology. 140:1427–1433. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
O'Connor N, Dargan PI and Jones AL:
Hepatocellular damage from non-steroidal anti-inflammatory drugs.
QJM. 96:787–791. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
McNeil JJ, Nelson MR, Woods RL, Lockery
JE, Wolfe R, Reid CM, Kirpach B, Shah RC, Ives DG, Storey E, et al:
Effect of aspirin on all-cause mortality in the healthy elderly. N
Engl J Med. 379:1519–1528. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Burn J, Gerdes AM, Macrae F, Mecklin JP,
Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L,
et al: Long-term effect of aspirin on cancer risk in carriers of
hereditary colorectal cancer: An analysis from the CAPP2 randomised
controlled trial. Lancet. 378:2081–2087. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Würtz M and Grove EL: Interindividual
variability in the efficacy of oral antiplatelet drugs:
Definitions, mechanisms and clinical importance. Curr Pharm Des.
18:5344–5361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Rocca B and Petrucci G: Variability in the
responsiveness to low-dose aspirin: Pharmacological and
disease-related mechanisms. Thrombosis. 2012:3767212012. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Joharatnam-Hogan N, Cafferty F, Hubner R,
Swinson D, Sothi S, Gupta K, Falk S, Patel K, Warner N, Kunene V,
et al: Aspirin as an adjuvant treatment for cancer: Feasibility
results from the Add-Aspirin randomised trial. Lancet Gastroenterol
Hepatol. 4:854–862. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Kaufman DW, Kelly JP, Wiholm BE, Laszlo A,
Sheehan JE, Koff RS and Shapiro S: The risk of acute major upper
gastrointestinal bleeding among users of aspirin and ibuprofen at
various levels of alcohol consumption. Am J Gastroenterol.
94:3189–3196. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Hernández-Díaz S and García Rodríguez LA:
Cardioprotective aspirin users and their excess risk of upper
gastrointestinal complications. BMC Med. 4:22–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Bhatt DL, Scheiman J, Abraham NS, Antman
EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW and Quigley EM;
American College of Cardiology Foundation Task Force on Clinical
Expert Consensus Documents, : ACCF/ACG/AHA 2008 expert consensus
document on reducing the gastrointestinal risks of antiplatelet
therapy and NSAID use: A Report of the American College of
Cardiology Foundation Task Force on Clinical Expert Consensus
Documents. Circulation. 118:1894–1909. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Kelly JP, Kaufman DW, Jurgelon JM, Sheehan
J, Koff RS and Shapiro S: Risk of aspirin-associated major
upper-gastrointestinal bleeding with enteric-coated or buffered
product. Lancet. 348:1413–1416. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Lin KJ, Hernández-Díaz S and García
Rodríguez LA: Acid suppressants reduce risk of gastrointestinal
bleeding in patients on antithrombotic or anti-inflammatory
therapy. Gastroenterology. 141:71–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Sylvester KW, Cheng JW and Mehra MR:
Esomeprazole and aspirin fixed combination for the prevention of
cardiovascular events. Vasc Health Risk Manag. 9:245–254.
2013.PubMed/NCBI
|
|
111
|
Lanas A, Polo-Tomas M and Casado-Arroyo R:
The aspirin cardiovascular/gastrointestinal risk calculator-a tool
to aid clinicians in practice. Aliment Pharmacol Ther. 37:738–748.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Mo C, Sun G, Lu ML, Zhang L, Wang YZ, Sun
X and Yang YS: Proton pump inhibitors in prevention of low-dose
aspirin-associated upper gastrointestinal injuries. World J
Gastroenterol. 21:5382–5392. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Scally B, Emberson JR, Spata E, Reith C,
Davies K, Halls H, Holland L, Wilson K, Bhala N, Hawkey C, et al:
Effects of gastroprotectant drugs for the prevention and treatment
of peptic ulcer disease and its complications: A meta-analysis of
randomised trials. Lancet Gastroenterol Hepatol. 3:231–241. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Whellan DJ, Goldstein JL, Cryer BL, Eisen
GM, Lanas A, Miller AB, Scheiman JM, Fort JG, Zhang Y and O'Connor
C: PA32540 (a coordinated-delivery tablet of enteric-coated aspirin
325 mg and immediate-release omeprazole 40 mg) versus
enteric-coated aspirin 325 mg alone in subjects at risk for
aspirin-associated gastric ulcers: Results of two 6-month, phase 3
studies. Am Heart J. 168:495–502.e4. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Martín Merino E, Johansson S, Nagy P and
García Rodríguez LA: Effect of baseline gastrointestinal risk and
use of proton pump inhibitors on frequency of discontinuation of
aspirin for secondary cardiovascular prevention in united kingdom
primary care. Am J Cardiol. 112:1075–1082. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Dey AB: World report on ageing and health.
Indian J Med Res. 145:1502017. View Article : Google Scholar
|
|
117
|
Hull MA, Sprange K, Hepburn T, Tan W,
Shafayat A, Rees CJ, Clifford G, Logan RF, Loadman PM, Williams EA,
et al: Eicosapentaenoic acid and aspirin, alone and in combination,
for the prevention of colorectal adenomas (seAFOod Polyp Prevention
trial): A multicentre, randomised, double-blind,
placebo-controlled, 2×2 factorial trial. Lancet. 392:2583–2594.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Cole BF, Logan RF, Halabi S, Benamouzig R,
Sandler RS, Grainge MJ, Chaussade S and Baron JA: Aspirin for the
chemoprevention of colorectal adenomas: Meta-analysis of the
randomized trials. J Natl Cancer Inst. 101:256–266. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Cook NR, Lee IM, Zhang SM, Moorthy MV and
Buring JE: Alternate-day, low-dose aspirin and cancer risk:
Long-term observational follow-up of a randomized trial. Ann Intern
Med. 159:77–85. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Kuan YC, Huang KW, Lin CL, Luo JC and Kao
CH: Effects of aspirin or clopidogrel on colorectal cancer
chemoprevention in patients with type 2 diabetes mellitus. Cancers
(Basel). 11:14682019. View Article : Google Scholar
|
|
121
|
Rothwell PM, Wilson M, Price JF, Belch JF,
Meade TW and Mehta Z: Effect of daily aspirin on risk of cancer
metastasis: A study of incident cancers during randomised
controlled trials. Lancet. 379:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Chan FK, Leung Ki EL, Wong GL, Ching JY,
Tse YK, Au KW, Wu JC and Ng SC: Risks of bleeding recurrence and
cardiovascular events with continued aspirin use after lower
gastrointestinal hemorrhage. Gastroenterology. 151:271–277. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Casado Arroyo R, Polo-Tomas M, Roncales
MP, Scheiman J and Lanas A: Lower GI bleeding is more common than
upper among patients on dual antiplatelet therapy: Long-term
follow-up of a cohort of patients commonly using PPI co-therapy.
Heart. 98:718–723. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Smecuol E, Pinto Sanchez MI, Suarez A,
Argonz JE, Sugai E, Vazquez H, Litwin N, Piazuelo E, Meddings JB,
Bai JC and Lanas A: Low-dose aspirin affects the small bowel
mucosa: Results of a pilot study with a multidimensional
assessment. Clin Gastroenterol Hepatol. 7:524–529. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Moore RA, Derry S and McQuay HJ: Faecal
blood loss with aspirin, nonsteroidal anti-inflammatory drugs and
cyclo-oxygenase-2 selective inhibitors: Systematic review of
randomized trials using autologous chromium-labelled erythrocytes.
Arthritis Res Ther. 10:R72008. View
Article : Google Scholar : PubMed/NCBI
|
|
126
|
Endo H, Higurashi T, Hosono K, Sakai E,
Sekino Y, Iida H, Sakamoto Y, Koide T, Takahashi H, Yoneda M, et
al: Efficacy of Lactobacillus casei treatment on small bowel injury
in chronic low-dose aspirin users: A pilot randomized controlled
study. J Gastroenterol. 46:894–905. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Montalto M, Gallo A, Curigliano V,
D'Onofrio F, Santoro L, Covino M, Dalvai S, Gasbarrini A and
Gasbarrini G: Clinical trial: The effects of a probiotic mixture on
non-steroidal anti-inflammatory drug enteropathy-a randomized,
double-blind, cross-over, placebo-controlled study. Aliment
Pharmacol Ther. 32:209–214. 2010. View Article : Google Scholar : PubMed/NCBI
|
